A new thiazolidinedione, NC-2100, which is a weak PPAR-γ activator, exhibits potent antidiabetic effects and induces uncoupling protein 1 in white adipose tissue of KKAy obese mice

Diabetes

Volumn 49, Issue 5, 2000, Pages 759-767

  Fukui, Yuka ^a,c   Masui, Sei Ichiro ^c   Osada, Shiho ^b   Umesono, Kazuhiko ^b   Motojima, Kiyoto ^a  

^a TOHO UNIVERSITY   (Japan)

^b KYOTO UNIVERSITY   (Japan)

^c Nippon Chemiphar Co Ltd   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

2,4 THIAZOLIDINEDIONE DERIVATIVE; 5 [(7 BENZYLOXY 3 QUINOLYL)METHYL] 2,4 THIAZOLIDINEDIONE; ADENOSINE TRIPHOSPHATE; ANTIDIABETIC AGENT; COMPLEMENTARY DNA; GLUCOSE; MESSENGER RNA; NC 2100; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR; PIOGLITAZONE; ROSIGLITAZONE; TROGLITAZONE; UNCLASSIFIED DRUG; UNCOUPLING PROTEIN 1;

ANIMAL CELL; ANIMAL MODEL; ARTICLE; BODY WEIGHT; BROWN ADIPOSE TISSUE; CONTROLLED STUDY; DIABETES MELLITUS; DRUG EFFECT; GLUCOSE BLOOD LEVEL; INSULIN RESISTANCE; MALE; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; NUCLEOTIDE SEQUENCE; OBESITY; PRIORITY JOURNAL;

EID: 0034085884     PISSN: 00121797     EISSN: None     Source Type: Journal    
DOI: 10.2337/diabetes.49.5.759     Document Type: Article

References (50)

1. Granner DK, O'Brien RM: Molecular physiology and genetics of NIDDM: importance of metabolic staging. Diabetes Care 15:369-395, 1992
2. Iwamoto Y, Kosaka T, Akanuma Y, Shigeta Y, Kaneko T. Effect of combination therapy of troglitazone and sulfonylureas in patients with type 2 diabetes who were poorly controlled by sulphonylurea therapy alone. Diabet Med 13:365-370, 1996
3. Fujiwara T, Yoshioka S, Yoshioka T, Ushiyama I, Horikoshi H: Characterization of new oral antidiabetic agent CS-045: studies in KK and ob/ob mice and Zucker fatty rats. Diabetes 37:1549-1558, 1988
4. Saltiel AR, Olefsky JM: Thiazolidinediones in the treatment of insulin resistance and type II diabetes. Diabetes 45:1661-1669, 1996
5. Ciaraldi TP, Gilmore A, Olefsky JM, Goldberg M, Heidenreich KA: In vitro studies on the action of CS-045: a new antidiabetic agent. Metabolism 39:1056-1062, 1990
6. Forman BM, Tontonoz P, Chen J, Brun RP, Spiegelman BM, Evans RM: 15-deoxy-Δ12,14-prostaglandin J2 is a ligand for the adipocyte determination factor PPARγ. Cell 83:803-812, 1995
7. Kliewer SA, Lenhard JM, Willson TM, Patel I, Morris DC, Lehman JM: A prostaglandin J2 metabolite binds peroxisome proliferator-activated receptor gamma and promotes adipocyte differentiation. Cell 83:813-819, 1995
8. Nolte RT, Wisely GB, Westin S, Cobb JE, Lambert MH, Kurokawa R, Rosenfeld MG, Willson TM, Glass CK, Milburn MV: Ligand binding and coactivator assembly of the peroxisome proliferator-activated receptor-γ. Nature 395:137-143, 1998
9. Lee SS, Pineau T, Drago J, Lee EJ, Owens JW, Kroetz DL, Fernandez-Salguero PM, Westphal H, Gonzalez FJ: Targeted disruption of the alpha isoform of the peroxisome proliferator-activated receptor gene in mice results in abolishment of the pleiotrupic effects of peroxisome proliferators. Mol Cell Biol 15:3012-3022, 1995
10. Ren B, Thelen AP, Peters JM, Gonzalez FJ, Jump DB: Polyunsaturated fatty acid suppression of hepatic fatty acid synthase and S14 gene expression does not require peroxisome proliferator-activated receptor α. J Biol Chem 272: 26827-26832, 1997
11. Kliewer SA, Sundseth SS, Jones SA, Brown PJ, Wisely GB, Koble CS, Devchand P, Wahli W, Willson TM, Lenhard JM, Lehmann JM: Fatty acids and eicosanoids regulate gene expression through direct interactions with peroxisome proliferator-activated receptors alpha and gamma. Proc Natl Acad Sci U S A 94:4318-4328, 1997
12. Lehmann JM, Moore LB, Smith-Oliver TA, Wilkson WO, Willson TM, Kliewer SA: An antidiabetic thiazolidinedione is a high affinity ligand for peroxisome proliferator-activated receptor γ (PPARγ). J Biol Chem 270:12953-12956, 1995
13. Saha AK, Kurowski TG, Colca JR, Ruderman NB: Lipid abnormalities in tissues of the KKAy mouse: effects of pioglitazone on malonyl-CoA and diacylglycerol. Am J Physiol 267:E95-E101, 1994
14. Shimizu H, Tsuchiya T, Sato N, Shimomura Y, Kobayashi I, Mori M: Troglitazone reduces plasma leptin concentration but increases hunger in NIDDM patients. Diabetes Care 21:1470-1474, 1998
15. Iwamoto Y, Kosaka K, Kusuya T, Akanuma Y, Shigeta Y, Kaneko T: Effects of troglitazone: a new hypoglycemic agent in patients with NIDDM poorly controlled by diet therapy. Diabetes Care 19:151-156, 1996
16. Bouillaud F, Ricquier D, Thibault J, Weissenbach J: Molecular approach to thermogenesis in brown adipose tissue: cDNA cloning of the mitochondrial uncoupling protein. Proc Natl Acad Sci USA 82:445-448, 1985
17. Fleury C, Neverova M, Collins S, Raimbault S, Champigny O, Levi-Meyrueis C, Bouillaud F, Seldin MF, Surwit RS, Ricquier D, Warden CH: Uncoupling protein-2: a novel gene linked to obesity and hyperinsulinemia. Nat Genet 15:236-246, 1997
18. 3-adrenergic agonists, and leptin. J Biol Chem 272:24129-24132, 1997
19. Skulachev VP: Fatty acid circuit as a physiological mechanism of uncoupling of oxidative phosphorylation. FEBS Lett 294:158-162, 1991
20. Yoshida T, Fujita T, Kanai T, Aizawa Y, Kurumada T, Hasegawa K, Horikoshi H: Studies on hindered phenols and analogues. I. Hypolipidemic and hypoglycemic agents with ability to inhibit lipid peroxidation. J Med Chem 32:421-428, 1989
21. Sohda T, Momose Y, Meguro K, Kawamatsu Y, Sugiyama Y, Ikeda H: Studies on antidiabetic agents. Arzneimittelforschung 40:37-42, 1990
22. Cantello BC, Cawthorne MA, Cottam GP, Duff PT, Haigh D, Hindley RM, Lister CA, Smith SA, Thurlby PL: [[ω-(heterocyclylamino)alkoxy]benzyl]-2,4-thiazolidinediones as potent antihyperglycemic agents. J Med Chem 37:3977-3985, 1994
23. Rubin CS, Hirsch A, Fyng C, Rosen OR: Development of hormone receptors and hormonal responsiveness in vitro. J Biol Chem 253:7570-7578, 1978
24. Wise LS, Green H: Participation of one isozyme of cytosolic glycerophosphate dehydrogenase in the adipose conversion. J Biol Chem 254:273-275, 1979
25. Lehman JM, Lenhard JM, Oliver BB, Ringold GM, Kliewer SA: Peroxisome proliferator-activated receptors α and γ are activated by indomethacin and other non-steroidal anti-inflammatory drugs. J Biol Chem 272:3406-3410, 1997
26. Formann BM, Umesono K, Chen J, Evans RM: Unique response pathways are established by allosteric interactions among nuclear hormone receptors. Cell 81:541-550, 1995
27. Chomczyski P, Sacchi N: Single-step method of RNA isolation by acid guanidinium thiocyanate-phenol-chloroform extraction. Anal Biochem 162:156-159, 1987
28. Motojima K, Peters JM, Gonzalez FJ: PPARα mediates peroxisome proliferator-induced transcriptional repression of nonperoxisomal gene expression in mouse. Biochem Biophys Res Commun 230:155-158, 1997
29. Motojima K, Passilly P, Peters JM, Gonzalez FJ, Latruffe N: Expression of putative fatty acid transporter genes is regulated by peroxisome proliferator-activated receptor α and γ activators in a tissue- and inducer-specific manner. J Biol Chem 273:16710-16714, 1998
30. Jacobsson A, Stadler U, Glotzer MA, Kozak LP: Mitochondrial uncoupling protein from mouse brown fat: molecular cloning, genetic mapping, and mRNA expression. J Biol Chem 260:16250-16254, 1985
31. Yoshitomi H, Yamazaki K, Tanaka I: Cloning of mouse uncoupling protein 3 cDNA and 5′-flanking region, and its genetic map. Gene 215:77-84, 1998
32. Lindquist PJ, Svensson LT, Alexson SE: Molecular cloning of the peroxisome proliferator-induced 46-kDa cytosolic acyl-CoA thioesterase from mouse and rat liver: recombinant expression in Escherichia coli tissue expression, and nutritional regulation. Eur J Biochem 251:631-640, 1998
33. Berger J, Truppe C, Neumann H, Forss-Petter S: cDNA cloning and mRNA dis-tribution of a mouse very long-chain acyl-CoA synthetase. FEBS Lett 425:305-309, 1998
34. Tweedie S, Edwards Y: cDNA sequence for mouse heart fatty acid binding protein, H-FABP. Nucleic Acids Res 17:4374, 1989
35. Staels B, Tol AV, Andren T, Auwerx J: Fibrates influence the expression of genes involved in lipoprotein metabolism in a tissue-selective manner in the rat. Arterioscler Thromb 12:286-294, 1992
36. Aubert J, Champigny O, Saint-Marc P, Negrel R, Collins S, Ricquier D, Ailhaud G: Up-regulation of UCP-2 gene expression by PPAR agonists in preadipose and adipose cells. Biochem Biophys Res Commun 238:606-611, 1997
37. Foellmi-Adams LA, Wyse BM, Herron D, Nedergaard J, Kletzien RF: Induction of uncoupling protein in brown adipose tissue: synergy between norepinephrine and pioglitazone, an insulin-sensitizing agent. Biochem Pharmacol 52:693-701, 1996
38. Daikoku T, Shinohara Y, Shima A, Yamazaki N, Terada H: Dramatic enhancement of the specific expression of the heart-type fatty acid binding protein in rat adipose tissue by cold exposure. FEBS Lett 410:383-386, 1997
39. Hirsch D, Stahl A, Lodish H: A family of fatty acid transporters conserved from mycobacterium to man. Proc Natl Acad Sci U S A 95:8625-8629, 1998
40. Nolte RT, Wisely GB, Westin S, Cobb JE, Lambert MH, Kurokawa R, Rosenfeld MG, Willson TM, Glass CK, Milburn MV: Ligand binding and co-activator assembly of the peroxisome proliferator-activated receptor-γ. Nature 395:137-143, 1998
41. Tontonoz P, Hu E, Spiegelman BM: Stimulation of adipogenesis in fibroblast by PPARγ2, a lipid-activated transcription factor. Cell 79:1147-1156, 1994
42. Walker AB, Naderali EK, Chattington PD, Buckingham RE, Williams G: Differential vasoactive effects of the insulin sensitizers rosiglitazone (BRL 49653) and troglitazone on human small arteries in vitro. Diabetes 47:810-814, 1998
43. Ishizuka T, Itaya S, Wada H, Ishizawa M, Kimura M, Kajita K, Kanoh Y, Miura A, Muto N, Yasuda K: Differential effect of the antidiabetic thiazolidinediones troglitazone and pioglitazone on human platelet aggregation mechanism. Diabetes 47:1494-1500, 1998
44. Reginato MJ, Bailey ST, Krakow SL, Minami C, Ishii S, Tanaka H, Lazar MA: A potent antidiabetic thiazolidinedione with unique peroxisome proliferator-activated receptor γ-activating properties. J Biol Chem 273:32679-32684, 1998
45. Sears IB, MacGinnitie MA, Kovacs LG, Graves RA: Differentiation-dependent expression of the brown adipocyte uncoupling protein gene: regulation by peroxisome proliferator-activated receptor γ. Mol Cell Biol 16:11410-3419, 1996
46. Guerra C, Koza RA, Yamashita H, Walsh K, Kozak LP: Emergence of brown adipocytes in white fat in mice is under genetic control. J Clin Invest 102:412-420, 1998
47. Puigserver P, Wu Z, Park CW, Graves R, Wright M, Spiegelman BM: A cold-inducible coactivator of nuclear receptors linked to adaptive thermogenesis. Cell 92:829-839, 1998
48. 3-adrenergic agonist. J Clin Invest 97:2898-2904, 1996
49. Kelly LJ, Vicario PP, Thompson GM, Candelore MR, Doebber TW, Ventre J, Wu MS, Meurer R, Forrest MJ, Conner MW, Cascieri MA, Moller DE: Peroxisome proliferator-activated receptors γ and α mediate in vivo regulation of uncoupling protein (UCP-1, UCP-2, UCP-3) gene expression. Endocrinology 139: 4920-4927, 1998
50. Kopecky J, Clarke G, Enerback S, Spiegelman B, Kozak LP: Expression of the mitochondrial uncoupling protein gene from the aP2 gene promoter prevents genetic obesity. J Clin Invest 96:2914-2923, 1995